159 related articles for article (PubMed ID: 30729850)
1. The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.
Seetasith A; Wong W; Tse J; Burudpakdee C
J Med Econ; 2019 May; 22(5):414-420. PubMed ID: 30729850
[TBL] [Abstract][Full Text] [Related]
2. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
Sheinson D; Wong WB; Wu N; Mansfield AS
Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
[TBL] [Abstract][Full Text] [Related]
3. Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines.
Wong WB; Donahue A; Thiesen J; Yeaw J
J Manag Care Spec Pharm; 2023 Mar; 29(3):324-334. PubMed ID: 36692908
[No Abstract] [Full Text] [Related]
4. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
Doshi JA; Li P; Huo H; Pettit AR; Armstrong KA
J Clin Oncol; 2018 Feb; 36(5):476-482. PubMed ID: 29261440
[TBL] [Abstract][Full Text] [Related]
5. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
Navar AM; Taylor B; Mulder H; Fievitz E; Monda KL; Fievitz A; Maya JF; López JAG; Peterson ED
JAMA Cardiol; 2017 Nov; 2(11):1217-1225. PubMed ID: 28973087
[TBL] [Abstract][Full Text] [Related]
6. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
Ingham M; Sadik K; Zhao X; Song J; Fendrick AM
J Manag Care Spec Pharm; 2023 Sep; 29(9):1084-1092. PubMed ID: 37548953
[No Abstract] [Full Text] [Related]
7. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE).
Karter AJ; Parker MM; Solomon MD; Lyles CR; Adams AS; Moffet HH; Reed ME
Health Serv Res; 2018 Apr; 53(2):1227-1247. PubMed ID: 28474736
[TBL] [Abstract][Full Text] [Related]
8. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
[TBL] [Abstract][Full Text] [Related]
9. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.
Guérin A; Sasane M; Wakelee H; Zhang J; Culver K; Dea K; Nitulescu R; Galebach P; Macalalad AR
Curr Med Res Opin; 2015 Aug; 31(8):1587-97. PubMed ID: 26029864
[TBL] [Abstract][Full Text] [Related]
10. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.
Zheng N; Zhang Y; Zeng Y; Ma Q; Zhang R; Zhao Q; Lu C; Tian J; Wang Z; Tang H; Luo N; Xiao H; He Y; Wu F; Li L
Target Oncol; 2023 Jul; 18(4):625-636. PubMed ID: 37351800
[TBL] [Abstract][Full Text] [Related]
11. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
12. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
13. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.
Farano JL; Kandah HM
J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209
[TBL] [Abstract][Full Text] [Related]
14. Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Ali A; Abdel-Malek RR
Crit Rev Oncol Hematol; 2019 Feb; 134():56-64. PubMed ID: 30771874
[TBL] [Abstract][Full Text] [Related]
15. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system.
Brouwer E; Yeung K; Barthold D; Hansen R
J Manag Care Spec Pharm; 2021 Jun; 27(6):732-742. PubMed ID: 34057391
[No Abstract] [Full Text] [Related]
16. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
Lu S; Yu Y; Fu S; Ren H
PLoS One; 2018; 13(10):e0205827. PubMed ID: 30352060
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer.
Hess LM; Louder A; Winfree K; Zhu YE; Oton AB; Nair R
J Manag Care Spec Pharm; 2017 Jun; 23(6):643-652. PubMed ID: 28530522
[TBL] [Abstract][Full Text] [Related]
19. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
20. Patient perceptions of copay card utilization and policies.
Cavalier D; Doherty B; Geonnotti G; Patel A; Peters W; Zona S; Shea L
J Mark Access Health Policy; 2023; 11(1):2254586. PubMed ID: 37692554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]